Study #2018-1164
Development & Evaluation of a Quantitative HP MRI Clinical Prostate Cancer Exam
MD Anderson Study Status
Not Accepting
Treatment Agent
Description
This trial examines if a prostate magnetic resonance spectroscopic imaging can be performed on a 3T scanner using an investigational contrast called hyperpolarized 13-C pyruvate for the development of a clinical prostate cancer exam. 3T refers to the strength of the magnetic resonance spectroscopic imaging (MRSI) machine. MRSI is a magnetic resonance imaging (MRI) technique that can show certain chemical differences in healthy and diseased prostate tumor tissue compared to standard multiparametric MRI that may not detect the tumor. Hyperpolarized (HP) 13-C pyruvate is a contrast drug that may help the scanner see the tumor site better during imaging. Hyperpolarization of 13-C pyruvate may allow pyruvate and its metabolites to be detected upon injection, which in turn, allow the prostate cancer to be found and treated.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Prostate Adenocarcinoma
Study phase:
Physician name:
Tharakeswara Bathala
Department:
Abdominal Imaging Department
For general questions about clinical trials:
1-844-285-5619
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.